Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients – Moderna Investor Relations February 22, 2023
Israeli ‘terror’ designation of Palestinian NGOs sparks furious backlash October 22, 2021October 22, 2021
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis February 23, 2021February 23, 2021
State Department revokes Houthis’ terror designation despite attack on Saudi airport February 13, 2021February 12, 2021